In summary, while myeloid-specific Acly-deficiency modulated the relative abundance of different myeloid and lymphoid immune cell subsets, this did not translate into a significantly altered TAM phenotype and had no effect on tumor growth in the MC38 tumor model. Here, ACLY is linked to neoplasm.